Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Implications of the microbiome after pancreatic cancer resection with regard to morbidity and mortality.

Expert review of gastroenterology & hepatology·2024
Same author

Diminished placental Factor XIIIA1 expression associates with pre-conception antiretroviral treatment and preterm birth in pregnant people living with HIV.

bioRxiv : the preprint server for biology·2024
Same author

A randomized phase II trial to examine modified vaccinia Ankara-5T4 vaccine in patients with relapsed asymptomatic ovarian cancer (TRIOC).

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2024
Same author

Impact of tertiary lymphoid structures on prognosis and therapeutic response in pancreatic ductal adenocarcinoma.

HPB : the official journal of the International Hepato Pancreato Biliary Association·2024
Same author

Advances in Immunotherapeutics in Pancreatic Ductal Adenocarcinoma.

Cancers·2023
Same author

Cancer cell-derived extracellular vesicles activate hepatic stellate cells in colorectal cancer.

Expert review of molecular diagnostics·2023

Related Experiment Video

Updated: Mar 30, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.9K

Immunohistochemistry Biomarkers in Nonmuscle Invasive Bladder Cancer.

Alana D Ranzi1, Jéssica N L da Silva, Túlio M Graziottin

  • 1*Research Laboratory of Pathology, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, Brazil †Departament of Urology, Hospital Santa Rita, Hospital system of the Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Brazil ‡Department of Microbial & Cellular Sciences, Faculty of Health & Medical Sciences, University of Surrey, Guildford, UK.

Applied Immunohistochemistry & Molecular Morphology : AIMM
|November 18, 2015
PubMed
Summary

Accurate bladder cancer (BCa) recurrence prediction needs better biomarkers. Combining markers like p53, Ki-67, CK20, and EN2 offers improved risk stratification for nonmuscle invasive bladder cancer (NMIBC).

More Related Videos

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

15.8K
3-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer
09:24

3-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer

Published on: September 13, 2018

9.6K

Related Experiment Videos

Last Updated: Mar 30, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.9K
A Murine Orthotopic Bladder Tumor Model and Tumor Detection System
06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

15.8K
3-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer
09:24

3-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer

Published on: September 13, 2018

9.6K

Area of Science:

  • Oncology
  • Urology
  • Biomarker Research

Background:

  • Bladder cancer (BCa) is a common urinary neoplasm, with muscle-invasive stages leading to significant mortality.
  • Nonmuscle invasive bladder cancer (NMIBC) accounts for 75-80% of cases but frequently recurs or progresses, necessitating long-term surveillance.
  • There is a critical need for validated biomarkers to detect BCa recurrence, enhancing patient quality of life and reducing healthcare costs.

Purpose of the Study:

  • To review and analyze immunohistochemistry prognostic biomarkers for nonmuscle invasive bladder cancer (NMIBC).
  • To evaluate the potential of combining multiple biomarkers for more accurate BCa recurrence prediction and risk stratification.

Main Methods:

  • Systematic review of 38 publications evaluating immunohistochemistry prognostic biomarkers in NMIBC.
  • Analysis and organization of studies based on evaluated markers and their findings regarding recurrence and progression.

Main Results:

  • The combination of independent, complementary biomarkers demonstrated a more accurate prognosis than single markers.
  • Biomarkers such as p53, Ki-67, CK20, and novel markers like EN2, when used together, may offer improved prediction of outcome.
  • Combined markers enhance risk stratification and clinical management of bladder cancer patients.

Conclusions:

  • A combination of established and novel biomarkers (p53, Ki-67, CK20, EN2) can significantly improve the prediction of nonmuscle invasive bladder cancer recurrence.
  • Utilizing multiple biomarkers enhances risk stratification, leading to better clinical management and outcomes for bladder cancer patients.
  • Validated biomarkers are crucial for improving surveillance, patient quality of life, and healthcare economics in bladder cancer care.